Slide 1: Immunome Corporate Presentation
Immunome Corporate Presentation August 13, 2024
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, any oral presentation of the slides by members of management of Immunome, Inc. (“Immunome”) or any person on its behalf, any question-
Slide 3: Establishing a Premier Targeted Oncology Company
Establishing a Premier Targeted Oncology Company Strong Foundation for Long-Term Success Long Term Corporate Vision • Experienced, successful leadership team • Develop first-in-class and best-in-class oncology therapies • Fully enrolled Phase 3 trial of AL102 for the treatment of • Organic pipeline
Slide 4: Recent Business Development Activity Expands Pipeline and Toolbox With Moderate Investment
Recent Business Development Activity Expands Pipeline and Toolbox With Moderate Investment Exclusive license of ADC assets Purchase of AL102, a Phase 3 asset for Purchase of assets related to over 25 • Preclinical ROR1 ADC with best-in-class treatment of desmoid tumors preclinical antibodies potenti
Slide 5: Pipeline Overview
Pipeline Overview Mechanism of Candidate Discovery Preclinical Phase 1 Phase 2 Phase 3 Next Anticipated Milestone Action Gamma Secretase Phase 3 Topline AL102 Inhibitor 2H25 IND Submission IM-1021 ROR1 ADC 1Q25 IND Submission IM-3050 FAP RLT 1Q25 - Undisclosed ADCs TBD - Undisclosed RLTs TBD IM-1021
Slide 6: ADC Strategy
ADC Strategy IMMUNOME 6
Slide 7: Target-Driven Development For the Next Generation of ADCs
Target-Driven Development For the Next Generation of ADCs Establish a broad pipeline and advance it through efficient clinical development decisions Immunome ADC Approach Systematic Development Through • Focus on oncology indications with high unmet need Clinical Proof of Concept • Identify novel or
Slide 8: ADC Activity is Concentrated in a Small Number of Targets
ADC Activity is Concentrated in a Small Number of Targets Identifying appropriate targets is a key challenge of ADC development Top 10 Targets Account for 54% of Active Clinical Downsides of Pursuing Most Popular Targets ADC Programs • Limitations of existing drugs may be difficult to overcome • Per
Slide 9: Systematically Evaluate Novel Targets for First-in-Class ADC Potential
Systematically Evaluate Novel Targets for First-in-Class ADC Potential Targets are evaluated for differential tumor Sources of Novel Targets and Antibodies expression and additional considerations Solid Tumor ADCs Immunome Discovery Platform Tivdak >30 identified targets Trodelvy Licensing/Acquisiti
Slide 10: Proprietary Payload Provides Opportunity to Develop Best-in-Class ADCs
Proprietary Payload Provides Opportunity to Develop Best-in-Class ADCs When conjugated to the same antibody, IMNM payload shows improved efficacy compared to DXd Proprietary ADC Payload HER2 ADC Constructed with IMNM • Camptothecin derivative/TOPO1 inhibitor Proprietary Payload Outperforms Enhertu •
Slide 11: Camptothecin Derivatives Are Well-Suited for ADCs Targeting Solid Tumors
Camptothecin Derivatives Are Well-Suited for ADCs Targeting Solid Tumors ADCs Containing Camptothecins Achieve Higher Enhertu (With Camptothecin Derivative Payload) DARs and Higher Clinical Doses Outperforms Kadcyla in Breast Cancer3 Progression-Free Survival 12 Clinical Doses of Selected ADCs1 Clin
Slide 12: Strong Demand for ADCs Provides Strategic Flexibility
Strong Demand for ADCs Provides Strategic Flexibility Opportunities to Transact at Value Inflection Points RECENT ADC TRANSACTIONS $2B TOTAL 1 $170M UPFRONT 3 $4B UPFRONT $1.5B+ IN MILESTONES $22B IN MILESTONES 5 $43B ACQUISITION 7 $175M UPFRONT $85M UPFRONT 4 $2B ACQUISITION 6 $9.3B2 IN MILESTONES
Slide 13: AL102
AL102 IMMUNOME 13
Slide 14: High Unmet Need for Patients with Desmoid Tumors
High Unmet Need for Patients with Desmoid Tumors Desmoid Tumors Are Debilitating, Painful, and Gamma Secretase Inhibitors For Treatment of Aggressive Desmoid Tumors • Gamma secretase inhibitors (GSIs) block the NOTCH ~1,000-1,650 ~5,500-7,000 pathway, a driver of desmoid tumors Patients diagnosed Ac
Slide 15: AL102 Data With Daily Dosing Shows Increased Response Compared to Nirogacestat Across All Measures
AL102 Data With Daily Dosing Shows Increased Response Compared to Nirogacestat Across All Measures ORR by RECIST • AL102 is being evaluated as an oral, once- Evaluable daily GSI for the treatment of desmoid tumors AL102 1.2mg QD1 75% ITT Median ToT 16.6 months • Phase 2 RINGSIDE data has shown deep,
Slide 16: Safety in Phase 2 Portion of RINGSIDE is consistent with GSI class
Safety in Phase 2 Portion of RINGSIDE is consistent with GSI class Study Population, n(%) AL102, 1.2mg QD, (n=14) Nirogacestat 150mg BID (n=69) Any Grade Grade ≥3 Any Grade Grade ≥3 Diarrhoea 13 (92.8) 2 (14.3) 58 (84) 11 (16) Nausea 8 (57.1) – 37 (54) 1 (1) Fatigue 7 (50) – 35 (51) 2 (3) Alopecia 7
Slide 17: RINGSIDE study design: Phase 3
RINGSIDE study design: Phase 3 PART B Key Inclusion Criteria Endpoints • Relapsed/refractory or treatment- • Primary: PFS naïve, with PD (per RECIST) • Secondary: ORR & DOR by BICR, in last 12 months PROs, Safety • Age ≥12 • Exploratory: MRI T1 & T2, ORR & • Measurable Lesion or MRI or CT DOR by inv
Slide 18: Programs: ROR1 ADC
Programs: ROR1 ADC IMMUNOME 18
Slide 19: ROR1 Is a Clinically Validated ADC Target
ROR1 Is a Clinically Validated ADC Target ROR1 MK-2140 Objective Response Rate In Three • Receptor with oncofetal expression pattern1 Pretreated Lymphoma Indications • Little or no expression in healthy tissue • Expressed on solid and liquid tumors 60% 50% 14% PR CR 12% MK-2140 40% • MK-2140 (former
Slide 20: Significant Opportunity for ROR1 in Solid Tumors
Significant Opportunity for ROR1 in Solid Tumors Potential ROR1 indications include diseases with ROR1 target biology presents challenges to large patient population and high unmet need developing a successful ADC for ROR1 positive solid tumors 100% • Moderate to low expression levels 90% 80% • Slow
Slide 21: IM-1021 is a ROR1 ADC with Potential for Improved Therapeutic Index
IM-1021 is a ROR1 ADC with Potential for Improved Therapeutic Index Name Linker / DAR Payload Development Status Zilovertamab Vedotin (MK-2140 / VLS-101) MC-VC-PAB MMAE: Tubulin Inhibitor Phase 2 completed; Cysteine conjugation no further updates Cleavable through Val-Cit DAR 4 NBE-002 Peptide linke
Slide 22: IM-1021 Shows Sustained Tumor Regression in TNBC Mouse Model
IM-1021 Shows Sustained Tumor Regression in TNBC Mouse Model IM-1021 demonstrates superior activity compared to MK-2140 at each respective dose IM-1021 Inhibits Tumor Growth in MDA-MB-468 No Weight Loss Observed Model (Triple Negative Breast Cancer) Tumor Volume (mm3) % BW Change Dose QWx3, i.v. IMM
Slide 23: Clinical Development Plan: Rapid Evaluation of Clinical PoC Followed by Pivotal Studies
Clinical Development Plan: Rapid Evaluation of Clinical PoC Followed by Pivotal Studies Across Multiple Indications Solid tumor expansion Pivotal Clinical Studies Indications including NSCLC, breast • Criteria for selecting indications cancer, prostate cancer, pancreatic cancer, and gastric cancer1
Slide 24: Programs: FAP RLT
Programs: FAP RLT IMMUNOME 24
Slide 25: FAP Is a Promising RLT Target with Pan-Cancer Potential
FAP Is a Promising RLT Target with Pan-Cancer Potential Fibroblast Activation Protein (FAP) is a cell surface FAP imaging shows high expression across protease with low expression in normal tissue 15 distinct tumor types • FAP is overexpressed on cancer-associated fibroblasts, the most common tumor
Slide 26: Immunome 177Lu-FAP Candidates are Rationally Designed and Systematically Screened
Immunome 177Lu-FAP Candidates are Rationally Designed and Systematically Screened Immunome Approach Proven structure used by Immunome has systematically selected Example Structure: Pluvicto and Lutathera to a ligand, linker, albumin binding Optimized linker deliver Lu-177 isotope reduces non-specifi
Slide 27: Incorporating Albumin Binders into Radioligand Therapies Improves In Vivo PK Profile
Incorporating Albumin Binders into Radioligand Therapies Improves In Vivo PK Profile and Biodistribution Enhanced pharmacokinetics may lead to superior tumor absorbed dose Total Absorbed Dose Rat IV PK Albumin Binding 600 100000 Albumin Binding Weak 10000 Moderate 500 Weak concentration Strong Moder
Slide 28: IM-3050 is a 177Lu-FAP Candidate with Best-in-Class Potential
IM-3050 is a 177Lu-FAP Candidate with Best-in-Class Potential In vivo data show single dose antitumor activity and tolerability Tumor Regression in U87MG Model No Weight Loss Observed Potential Best-in-Class Characteristics 177 Lu-Mi-003 Radiotherapy in U87MG tumors Sub-nanomolar affinity Vehicle
Slide 29: Immunome Discovery Platform
Immunome Discovery Platform IMMUNOME 29
Slide 30: Antibody and Target Discovery Engine
Antibody and Target Discovery Engine Harnessing the immune system to inform the next generation of cancer therapy PATIENT RESPONSES UNVEIL NOVEL DISEASE TARGETS 01 02 03 04 Patients with cancer generate Memory B cells are isolated, Antibodies are selected using Novel antibody-target pairs are memory
Slide 31: Immunome Approach Identifies Both Validated and Novel Cancer Target
Immunome Approach Identifies Both Validated and Novel Cancer Target Identification of Clinically Validated Cancer Targets Immunome Technology Enhances Power Validates Immunome Approach of Antibody Screens • Memory B-cell response generated across course of disease • Competitor B-cell platforms restr
Slide 32: Strategic Discovery Collaboration with AbbVie
Strategic Discovery Collaboration with AbbVie Key Financial Terms • AbbVie option to purchase worldwide rights for up to 10 novel target-antibody pairs arising from three specified tumor types • $30M upfront payment • Eligible for additional payments up to: • $70M platform access payments (in additi
Slide 33: IP, Business Development, and Leadership
IP, Business Development, and Leadership IMMUNOME 33
Slide 34: Prosecuting a Multi-Layered IP Strategy
Prosecuting a Multi-Layered IP Strategy COMPOSITION OF MATTER • Over 100 patents and patent applications across more than 20 families as of November 2023 • Covers Immunome’s proprietary PLATFORM & DISCOVERY antibody sequences • Platform technologies and • Covers proprietary targeting discovery engin
Slide 35: Management Team with a Demonstrated Track Record of Success
Management Team with a Demonstrated Track Record of Success Clay Siegall, Ph.D. • Chief Executive Officer and Founder, Seagen (1998-2022) PRESIDENT & • Grew company to $2B+ revenue (2022) leading to $43B acquisition CHIEF EXECUTIVE OFFICER • Led development of 4 FDA-approved therapeutics • Raised ov
Slide 36: Building the Foundation of a Premier Targeted Oncology Company
Building the Foundation of a Premier Targeted Oncology Company • Experienced management team with headquarters in Bothell, WA • Fully enrolled Phase 3 trial for AL102 for the treatment of desmoid tumors • Two preclinical programs with best-in-class or first-in-class potential: • IM-1021: ROR1 ADC •